New Cancer Test Improves Diagnosis of Prostate Cancer, Product Significantly Improves Diagnostics for Men's Health Care

NEW YORK, May 4, 2018 (Newswire.com) - Recognizing that prostate cancer in men is misdiagnosed, NucleoBio Inc.™ is developing a new product, Prostac©, that will accurately reveal results of a prostate cancer screening. Currently, there is no test that differentiates between indolent and aggressive prostate cancer, and Prostac is the first assay of its kind that utilizes new and advanced technology to distinguish these two types of prostate cancer that differ vastly.

NucleoBio Inc. is developing and commercializing prostate cancer diagnostics and therapeutics, with the support of the Research Foundation of the City University of New York. The company’s product Prostac is a test kit that will significantly change the way medical professionals administer prostate cancer testing. “Prostac is a non-invasive, urine-based test that will resolve numerous flaws in existing prostate cancer screening methods,” said Charles Oyesile, M.D., Ph.D., NucleoBio Inc. CEO and co-founder. “Up to 75 percent of prostate-specific antigen tests given today return a false positive; the tests suggest there is prostate cancer when it’s actually not. As a result, patients are being misdiagnosed, overtreated and overcharged. These situations cause patients heightened anxiety and undue stress. Prostac is going to drastically improve health care for men and dramatically disrupt the health care industry.”

Prostac will reveal cancer-specific information from patients' biological samples.

Olorunseun Ogunwobi, M.D., Ph.D., Co-Founder/Chief Scientific Officer

Prostac harnesses genetics for the detection of cancer. Being a multiplex test, it will be more accurate than existing prostate cancer tests, such as PCA3 and PHI. It’s a molecular biomarker-based test that is non-invasive and urine-based. Prostac may eliminate the need for expensive and potentially harmful prostate biopsies. The lowered cost is encouraging for men who get annual exams. According to the American Cancer Society, prostate cancer is the most common cancer in American men and 164,690 new cases are forecasted in 2018. Men 65 or older and African-American men are considered a high-risk population.

The United States Patent and Trademark Office has already issued one of three patent applications for NucleoBio Inc. Developed at Hunter College of the City University of New York (CUNY), the university has been working with NucleoBio since the beginning. “We have a strong IP protection of the background technology and optioned the portfolio exclusively to NucleoBio,” said Neeti Mitra, senior manager-industrial liaison and licensing for CUNY’s Technology Commercialization Office (TCO). “We are confident that partnering with NucleoBio will help us commercialize this portfolio, which is our main goal at CUNY TCO.”

Prostac is significant because of its ability to detect new genetic elements in biological samples. “Prostac will reveal cancer-specific information from patients’ biological samples,” said Olorunseun Ogunwobi, M.D., Ph.D., NucleoBio Inc. co-founder and head of the Ogunwobi laboratory at Hunter College, CUNY. “Consequently, this product will be highly sought by hospitals and laboratories interested in non-invasive biomarker assays for the diagnosis of aggressive prostate cancer.”

The complete test kit is currently in development and corporate executives plan to market it globally. The molecular biomarker test, which is a quantitative polymerase chain reaction-based test, can be performed with the patient’s urine or blood. The test kit will contain several components and will be available to physicians and health care professionals at medical facilities that offer prostate cancer screening and men’s health care. Processing for Prostac will occur at CLIA-certified laboratories and other specialized laboratories.

To learn more, please visit www.nucleobio.net.

NucleoBio Inc. is a Delaware C-Corporation that uses genetics to produce accurate and non-invasive health care diagnostics and therapeutics. NucleoBio focuses on the most common solid organ cancers impacting people worldwide for which no reliable diagnostics exist and for which few therapies provide treatment free from adverse effects. These include prostate, pancreatic, breast, cervical and colon cancer. Founded in 2017, NucleoBio’s offices and laboratory space are located in New York City and its headquarters is in San Antonio.

The Research Foundation of the City University of New York (RFCUNY) is a not-for-profit educational corporation that manages private and government-sponsored programs at the City University of New York (CUNY). Since 1963, RFCUNY has provided CUNY (and non-CUNY clients more recently) with the administrative infrastructure that supports sponsored program activities.

Technology Commercialization Office (TCO) at the City of University of New York encourages, protects, markets and licenses worthy innovations at various campuses and centers. The TCO nurtures collaboration between academia and industries by championing sponsored research at various facilities within the university, by licensing of CUNY intellectual property to sponsors and other industry partners and by supporting formation of new start-up companies. In so doing, the TCO fosters economic development in local and global communities.

Media Contact Information:

Kelly Plessala
Sr. Director of Marketing
NucleoBio Inc.
110 East Houston Street
San Antonio, TX 78205
210-378-9856
[email protected]

Source: NucleoBio Inc.